Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alebund Pharmaceuticals (Jiangsu) EBITDA Margin % Related Terms
Alebund Pharmaceuticals (Jiangsu) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
EBITDA Margin %
-4,493.25
-1,952.26
HKSE:09637 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a EBITDA Margin % of -1,952.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #937 out of 960 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is Alebund Pharmaceuticals (Jiangsu)'s EBITDA Margin % too high?
Alebund Pharmaceuticals (Jiangsu)'s current EBITDA Margin % is -1,952.26%. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #937 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #937 out of 960 companies for EBITDA Margin %. This places Alebund Pharmaceuticals (Jiangsu) in the lower half of its industry. The industry median EBITDA Margin % is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.90, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current EBITDA Margin % is -1,952.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current EBITDA Margin % of -1,952.26%. The current EBITDA Margin % is -1,952.26%. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current EBITDA Margin % is -1,952.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
